|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy显示文摘Chimeric antigen receptor T-cell(CAR-T)therapy has greatly improved the disease remission rate and long-term survival rate of patients with relapsed/refractory hematological malignancies.[1-3]Currently,several commercial CAR-T products are available in the market and numerous CAR-T clinical trials have been conducted.Attention should be paid to the safety of CAR-T therapy.The main adverse effects of CAR-T therapy are cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS).[4] | Heng Mei Fangping Chen Yue Han Ming Hou He Huang Xiaojun Huang Yuhua Li Aibin Liang Qifa Liu Ting Niu Jun Peng Wenbin Qian Yongping Song Jianxiang Wang Ying Wang Depei Wu Kailin Xu Linhua Yang Renchi Yang Lei Zhang Liansheng Zhang Xi Zhang Xiaohui Zhang Weili Zhao Weidong Han Yu Hu | 2022 | Chinese Medical Journal2022，，14： | 4 |
| 2 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 3 | CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma显示文摘To the Editor:CD19-targeting chimeric antigen receptor T(CAR-T)cell therapy is a revolutionary immunotherapy in treating relapsed or refractory B lineage malignancies.However,relapse with CD19-negative tumor after treatment with anti-CD19 CAR-T cells has been reported in different types of B-cell lymphoid malignancies,with a percentage exceeding 10% in patients with acute lymphoblastic leukemia[1]and up to 38% in patients with non-Hodgkin lymphoma(NHL)[2]. | Wenhai Deng Panpan Chen Wen Lei Yang Xu Nengwen Xu Jeffrey J.Pu Aibin Liang Wenbin Qian | 2021 | Cancer Communications2021，41，9： | 4 |
| 4 | 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma显示文摘Adoptive cellular immunotherapy with chimeric antigen receptor(CAR)T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma(B-NHL).With increasing approval of CAR T-cell products and advances in CAR T cell therapy,CAR T cells are expected to be used in a growing number of cases.However,CAR T-cell-associated toxicities can be severe or even fatal,thus compromising the survival benefit from this therapy.Standardizing and studying the clinical management of these toxicities are imperative.In contrast to other hematological malignancies,such as acute lymphoblastic leukemia and multiple myeloma,anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features,most notably local cytokine-release syndrome(CRS).However,previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL.Consequently,we developed this consensus for the prevention,recognition,and management of these toxicities,on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions.This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management,and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS. | Ping Li Yang Liu Yun Liang Jian Bo Sujun Gao Yongxian Hu Yu Hu He Huang Xiaojun Huang Hongmei Jing Xiaoyan Ke Jianyong Li Yuhua Li Qifa Liu Peihua Lu Heng Mei Ting Niu Yongping Song Yuqin Song Liping Su Sanfang Tu Jianxiang Wang Depei Wu Zhao Wang Kailin Xu Zhitao Ying Qingming Yang Yajing Zhang Fengxia Shi Bin Zhang Huilai Zhang Xi Zhang Mingfeng Zhao Weili Zhao Xiangyu Zhao Liang Huang Jun Zhu Wenbin Qian Weidong Han Aibin Liang | 2023 | Cancer Biology & Medicine2023，20，2： | 3 |
| 5 | A highly sensitive SPE-liquid/liquid extraction-RPLC analytical method for the determination of 6β-hydroxycortisol and cortisol in cancer patients' urine显示文摘Objective: A highly sensitive SPE-liquid/liquid extraction RPLC method has been developed for the analysis of 6β-hydroxycortisol and cortisol in the urine of cancer patients. Methods: After SPE column purification and liquid-liquid extraction, the sample test solutions were analyzed with RPLC using a C18 analytical column. This improved analytical method has been validated for linearity, accuracy (recovery from urine), repeatability (within-day and between-day precision), specificity, sensitivity, and stability. This SPE-liquid/liquid extraction-RPLC is rapid, simple, accurate and reproducible. The technique is particularly useful for monitoring the CYP3A activity of cancer patients in clinical settings. The results are expressed as the ratio of 6β-hydroxycortisol to cortisol. Results: The CYP3A activity from a total of 153 samples was measured using this improved method. Considerable variation in the CYP3A activity of different cancer patients has been documented. Thus, personalized medical treatment based on the individual metabolic enzyme activity level is necessary. Conclusion: This new analytical method facilitates such individualized medical treatments. | Zhang Hong Fang Yu Li Ying Liang Aibin | 2010 | Journal of Medical Colleges of PLA(China)2010，25，2： | 3 |
| 6 | The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma显示文摘Chimeric antigen receptor T(CAR T)cell therapy has demonstrated efficacy in the treatment of haematologic malignancies.However,the accompanying adverse events,the most common of which is cytokine release syndrome(CRS),substantially limit its wide application.Due to its unique physiological characteristics,CRS in CAR T-cell treatment for B-cell non-Hodgkin lymphoma(BNHL)may exhibit some special features.Although existing guidelines had greatly promoted the recognition and management of CRS,many recommendations are not fully applicable to B-NHL.Therefore,it is imperative to identify responses that are specific to CRS observed following CAR T treatment for B-NHL.Based on underlying biological processes and known pathophysiological mechanisms,we tentatively propose a new model to illustrate the occurrence and evolution of CAR T-cell-therapy-related CRS in BNHL.In this model,tumour burden and bone marrow suppression are considered determinants of CRS.Novel phenomena after CAR T-cell infusion(such as local inflammatory response)are further identified.The proposed model will help us better understand the basic biology of CRS and recognize and manage it more rationally. | Jianshu Wei Yang Liu Chunmeng Wang Yajing Zhang Chuan Tong Guanghai Dai Wei Wang John E.J.Rasko J.Joseph Melenhorst Wenbin Qian Aibin Liang Weidong Han | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 2 |
| 7 | Development and Characterization of Microsatellite Markers for the Pacific Abalone (Haliotis discus) via EST Database Mining显示文摘The EST database of the Pacific abalone (Haliotis discus) was mined for developing microsatellite markers. A total of 1476 EST sequences were registered in GenBank when data mining was performed. Fifty sequences (approximately 3.4%) were found to contain one or more microsatellites. Based on the length and GC content of the flanking regions, cluster analysis and BLASTN, 13 microsatellite-containing ESTs were selected for PCR primer design. The results showed that 10 out of 13 primer pairs could amplify scorable PCR products and showed polymorphism. The number of alleles ranged from 2 to 13 and the values of Ho and He varied from 0.1222 to 0.8611 and 0.2449 to 0.9311, respectively. No significant linkage disequilibrium (LD) between any pairs of these loci was found, and 6 of 10 loci conformed to the Hardy-Weinberg equilibrium (HWE). These EST-SSRs are therefore potential tools for studies of intraspecies variation and hybrid identification. | ZHAN Aibin BAO Zhenmin WANG Mingling CHANG Dan YUAN Jian WANG Xiaolong HU Xiaoli LIANG Chengzhu HU Jingjie | 2008 | Journal of Ocean University of China2008，7，2： | 2 |
| 8 | 2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy显示文摘Immune thrombocytopenia(ITP)is an acquired disease characterized by isolated thrombocytopenia,which is one of the most common causes of thrombocytopenia during pregnancy.Women with ITP who have severe thrombocytopenia are at an increased risk for life-threatening obstetric complications.Therefore,we established this consensus statement on the diagnosis and management of ITP during pregnancy(detailed information is available in the Supplementary File,http://gffzz16e312a87a7141a5hn0kvp6wnbnn96o6o.ffgz.tsg.suse.edu.cn/A978). | Zhang Xiaohui Chen Fangping Chen Xiequn Cheng Yunfeng Fang Meiyun Feng Jianming Fu Haixia Gao Hong Han Yue He Aili Hou Ming Hu Yu Huang Ruibin Huang Wenrong Jing Zhicheng Kong Peiyan Liang Aibin Liang Meiying Liu Daihong Liu Junling Liu Lin Liu Xiaowei Ma Liangming Mei Heng Ni Heyu Niu Ting Peng Jun Qiao Jianlin Ren Jinhai Song Yongping Tang Liang V Tong Tong Wang Shaoyuan Wang Xin Wang Zhao Wei Hui Wu Depei Wu Guangsheng Xu Caigang Xu Xue Xu Yajing Yang Linhua Yang Renchi Yang Tonghua Yin Chenghong Yu Li Zhang Guangsen Zhang Lei Zhang Liansheng Zhang Xi Zhao Weili Zhao Yongqiang Zhou Daobin Zhou Hu Zhou Zeping Zhu Tienan Wang Jianliu Huang Xiaojun | 2022 | Chinese Medical Journal2022，，8： | 2 |
| 9 | Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?显示文摘Chimeric antigen receptor(CAR)T-cell therapy utilizes patients’own T lymphocytes that are engineered to attack cancer cells[1,2,3].With the US Food and Drug Administration(FDA)approval of four CD19-and one BCMA-targeted CAR therapy for B cell malignancies[4,5],CAR T-cell therapy has finally reached the status of a medicinal product. | Xiaolei Li Hanren Dai Xian Li Ping Li Wenbin Qian Aibin Liang Weidong Han | 2022 | Cellular & Molecular Immunology2022，19，1： | 2 |
| 10 | Epi-immunotherapy for cancers:rationales of epi-drugs in combination with immunotherapy and advances in clinical trials显示文摘Over the last two decades,several epi-drugs,immune checkpoint inhibitors(ICIs)and adoptive cell therapies have received clinical approval for use in certain types of cancer.However,monotherapy with epi-drugs or ICIs has shown limited efficacy in most cancer patients.Epigenetic agents have been shown to regulate the crosstalk between the tumor and host immunity to alleviate immune evasion,suggesting that epi-drugs can potentially synergize with immunotherapy.In this review,we discuss recent insights into the rationales of incorporating epigenetic therapy into immunotherapy,called epi-immunotherapy,and focus on an update of current clinical trials in both hematological and solid malignancies.Furthermore,we outline the future challenges and strategies in the field of cancer epi-immunotherapy. | Yang Xu Ping Li Yang Liu Dijia Xin Wen Lei Aibin Liang Weidong Han Wenbin Qian | 2022 | Cancer Communications2022，42，6： | 1 |
| 11 | Evidence of the predominance of passive symplastic phloem loading and sugar transport with leaf ageing in Camellia oleifera显示文摘Phloem loading and transport of sugar from leaves to sink tissues such as fruits are crucial for yield formation.Camellia oleifera is an evergreen horticultural crop with high value;however,its low production limits the development of the C.oleifera industry.In this study,using a combination of ultrastructural observation,fluorescence loss in photobleaching(FLIP)and inhibitor treatment,we revealed that C.oleifera leaves mainly adopt a symplastic loading route from mesophyll cells to the surrounding vascular bundle cells in minor veins.HPLC assays showed that sucrose is the main sugar transported and only a small amount of raffinose or stachyose was detected in petioles,supporting a passive symplastic loading route in C.oleifera leaves.Compared to leaves grown this year(LT),the carbohydrate synthesis capacity in leaves grown last year(LL)was decreased while LL retained more soluble sugar,suggesting a decrease in transport capacity with leaf ageing.TEM and tissue staining showed that a reduction in plasmodesmata density leads to a decline in the degree of cellular coupling and is responsible for the weakening transport capacity in older leaves.RNA-seq revealed several differentially expressed genes(DEGs)including CoPDCB1-1,CoSUT1 and CoSWEET12,which are likely involved in the regulation of phloem loading and sugar transport.An expression correlation network is constructed between PD-callose binding protein genes,sugar transporter genes and senescence-associated genes.Collectively,this study provides the evidence of the passive symplastic phloem loading pathway in C.oleifera leaves and constructs the correlation between sugar transport and leaf ageing. | Shiwen Yang Kehao Liang Yongjiang Sun Jinshun Zhang Yibo Cao Jing Zhou Aibin Wang Lingyun Zhang | 2023 | Horticultural Plant Journal2023，9，4： | 0 |
| 12 | Comparative transcriptome profiling reveals the defense pathways and mechanisms in the leaves and roots of blueberry to drought stress显示文摘Blueberry is an important horticultural plant that is very susceptible to drought.However,the molecular regulation mechanisms of blueberry tolerance to drought remain elusive.In this study,the transcriptome profile of blueberry by RNA-seq under different degrees of drought treatment were conducted and drought-related genes and pathways were screened using weighted gene co-expression network analysis(WGCNA)and Venn analysis.Interestingly,the leaves and roots of blueberry exhibited different expression patterns under drought treatment and differentially expressed genes(DEGs),GO terms and KEGG pathways were more enriched in leaves than in roots.The majority of DEGs were associated with signal transduction,transcriptional regulation,and metabolism.Eight key pathways and eight DEGs were shared both in leaves and roots.Notably,the pathway with the most core genes in leaves is the plant hormone signal transduction pathway,and in roots are the MAPK signaling pathway,reactive oxygen species metabolism and the key genes such as VcXTH3,VcPP2C51,and VcPNC1 were identified.For transcription factors,VcABR1,VcABF2,VcMYB108 and VcMYB93 are likely involved in drought response.In the metabolism category,VcCYP75A1 was likely involved in anthocyanin biosynthesis,and VcPNC1 in the monoterpenoid biosynthesis pathway.The eight DEGs markedly induced under drought exhibited differential expression in leaves and roots.Correspondingly,physiological assays showed that POD activity,ABA content,and anthocyanin biosynthesis in leaves and roots were significantly increased.Collectively,our study revealed the synergistic and distinct defense pathways and mechanisms in leaves and roots of blueberry and explored the potential regulatory network in blueberry response to drought stress. | Aibin Wang Lei Wang Kui Liu Kehao Liang Shiwen Yang Yibo Cao Lingyun Zhang | 2022 | Fruit Research2022，2，1： | 0 |
| 13 | 建立具有体内胚内和胚外发育潜能的多能干细胞显示文摘文章简介在已知的体外培养的干细胞类型当中,多能干细胞具有最高的发育潜能,能够形成构成成年个体的所有细胞类型。但是,多能干细胞很难在体内发育过程中形成胚外的胎盘组织。 | Yang Yang Bei Liu Jun Xu Jinlin Wang Jun Wu Cheng Shi Yaxing Xu Jiebin Dong Chengyan Wang Weifeng Lai Jialiang Zhu Liang Xiong Dicong Zhu Xiang Li Weifeng Yang Takayoshi Yamauchi Atsushi Sugawara Zhongwei Li Fangyuan Sun Xiangyun Li Chen Li Aibin He Yaqin Du Ting Wang Chaoran Zhao Haibo Li Xiaochun Chi Hongquan Zhang Yifang Liu Cheng Li Shuguang Duo Ming Yin 沈浣 Juan Carlos Izpisua Belmonte 邓宏魁 | 2018 | 科学新闻2018，0，4： | 0 |
| 14 | Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy显示文摘Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T(CAR-T)cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma(r/r NHL)have not been well characterized.In this study,we found that the different sites of extranodal involvement may affect response,overall survival(OS),and progression-free survival(PFS)in patients with r/r NHL treated with anti-CD19 CAR-T cells.In a cohort of 32 treated patients,12(37.5%)and 8(25%)patients exhibited soft tissue lymphoma and bone marrow(BM)infiltrations,respectively,and 13(41%)patients exhibited infiltration at other sites.The factors that may affect prognosis were identified through multivariable analysis.As an independent risk factor,soft tissue infiltration was the only factor significantly correlated with adverse prognosis(P<0.05),whereas other factors did not reach statistical significance.Furthermore,the site of extranodal tumor infiltration significantly and negatively affected OS and PFS in patients with r/r NHL treated with anti-CD19 CAR-T cell therapy.PFS and OS in patients with BM involvement were not significantly different from those of patients with lymph node involvement alone.Thus,anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration. | Lili Zhou Ping Li Shiguang Ye Xiaochen Tang Junbang Wang Jie Liu Aibin Liang | 2020 | Frontiers of Medicine2020，14，6： | 0 |
| 15 | Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma显示文摘Mantle cell lymphoma(MCL)is a distinct histological type of B-cell lymphoma with a poor prognosis.Several agents,such as proteasome inhibitors,immunomodulatory drugs,and inhibitors of B cell lymphoma-2 and Bruton’s tyrosine kinase have shown efficacy for relapsed or refractory(r/r)MCL but often have short-term responses.Chimeric antigen receptor(CAR)T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin’s lymphoma.However,long-term safety and tolerability associated with CAR T-cell therapy are not defined well,especially in MCL.In this report,we described a 70-year-old patient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cell therapy.CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL,who are generally elderly and have comorbid conditions. | Ping Li Ningxin Dong Yu Zeng Jie Liu Xiaochen Tang Junbang Wang Wenjun Zhang Shiguang Ye Lili Zhou Alex Hongsheng Chang Aibin Liang | 2020 | Frontiers of Medicine2020，14，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员